Bruton Tyrosine Kinase Inhibitors in B-Cell Malignancies: Multidisciplinary Perspectives on Managing and Maximizing Care

Do you know how adverse events (AEs) associated with Bruton tyrosine kinase (BTK) inhibitors affect patients’ lives and how best to manage these events? Credit available for this activity expires: 11/15/24 Earn Credit / Learning Objectives & Disclosures: https://www.medscape.org/viewarticle/998369?ecd=bdc_podcast_libsyn_mscpedu